Esophageal hypomotility and spastic motor disorders: Current diagnosis and treatment

Current Gastroenterology Reports

Volumn 16, Issue 11, 2014, Pages 1-10

  Valdovinos, Miguel A ^a   Zavala Solares, Monica R ^a   Coss Adame, Enrique ^a  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

Chest pain; Distal esophageal spasm; Dysphagia; Esophageal hypomotility; High resolution manometry; Hypercontractile esophagus; Ineffective esophageal motility; Jackhammer esophagus; Nutcracker esophagus; Weak peristalsis

Indexed keywords

BOTULINUM TOXIN A; CALCIUM CHANNEL BLOCKING AGENT; HEMOGLOBIN; IMIPRAMINE; NIFEDIPINE; NITRATE; NITRIC OXIDE; PHOSPHODIESTERASE; PHOSPHODIESTERASE INHIBITOR; PLACEBO; PROTON PUMP INHIBITOR; SERTRALINE; SILDENAFIL; SPASMOLYTIC AGENT; VENLAFAXINE;

ARTICLE; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; DYSPHAGIA; ESOPHAGEAL HYPOMOTILITY; ESOPHAGOGRAPHY; ESOPHAGUS ACHALASIA; ESOPHAGUS FUNCTION DISORDER; ESOPHAGUS MOTILITY; ESOPHAGUS PRESSURE; GASTROESOPHAGEAL REFLUX; HUMAN; MANOMETRY; MOTOR DYSFUNCTION; MUSCLE EXCITATION; MYOTOMY; PATHOPHYSIOLOGY; PREVALENCE; SMOOTH MUSCLE CONTRACTION; SPASTIC MOTOR DISORDER; STOMACH FUNDOPLICATION; THORAX PAIN; VELOCITY; ESOPHAGEAL MOTILITY DISORDERS; ESOPHAGEAL PH MONITORING; ESOPHAGEAL SPASM, DIFFUSE; ESOPHAGOSCOPY; PERISTALSIS; PHYSIOLOGY; PROCEDURES;

ESOPHAGEAL MOTILITY DISORDERS; ESOPHAGEAL PH MONITORING; ESOPHAGEAL SPASM, DIFFUSE; ESOPHAGOSCOPY; HUMANS; MANOMETRY; PERISTALSIS;

EID: 84948409344     PISSN: 15228037     EISSN: 1534312X     Source Type: Journal    
DOI: 10.1007/s11894-014-0421-1     Document Type: Article

References (96)

1. Spechler SJ, Castell DO. Classification of oesophageal motility abnormalities. Gut. 2001;49:145–51.
2. Bredenoord AJ, Fox M, Kahrilas PJ, Pandolfino JE, Schwizer W, Smout AJ, et al. Chicago classification criteria of esophageal motility disorders defined in high resolution esophageal pressure topography. Neurogastroenterol Motil. 2012;24 Suppl 1:57–65. This is the most recent revised version of the Chicago Classification which contains a hierarchical algorithm for the diagnosis of esophageal motor disorders.
3. Pandolfino JE, Ghosh SK, Rice J, Clarke JO, Kwiatek MA, Kahrilas PJ. Classifying esophageal motility by pressure topography characteristics: a study of 400 patients and 75 controls. Am J Gastroenterol. 2008;103:27–37.
4. Almansa C, Heckman MG, DeVault KR, Bouras E, Achem SR. Esophageal spasm: demographic, clinical, radiographic, and manometric features in 108 patients. Dis Esophagus. 2012;25:214–21. This is the largest published case series of DES that describes the heterogenous presentation of distal spasm.
5. Tsuboi K, Mittal SK. Diffuse esophageal spasm: has the term lost its relevance? Analysis of 217 cases. Dis Esophagus. 2010.
6. Richter JE, Castell DO. Diffuse esophageal spasm: a reappraisal. Ann Intern Med. 1984;100:242–5.
7. Pandolfino JE, Roman S, Carlson D, Luger D, Bidari K, Boris L, et al. Distal esophageal spasm in high-resolution esophageal pressure topography: defining clinical phenotypes. Gastroenterology. 2011;141:469–75. This study demonstrated that a short distal latency (DL) is a better biomarker instead of contraction velocity to diagnose DES. Only 2% of patients with nonobstructive dysphagia had distal spasm using DL.
8. Roman S, Kahrilas PJ. Management of spastic disorders of the esophagus. Gastroenterol Clin N Am. 2013;42:27–43.
9. Achem SR, Gerson LB. Distal esophageal spasm: an update. Curr Gastroenterol Rep. 2013;15:325.
10. Goyal RK, Chaudhury A. Physiology of normal esophageal motility. J Clin Gastroenterol. 2008;42:610–9.
11. Murray J, Du C, Ledlow A, Bates JN, Conklin JL. Nitric oxide: mediator of nonadrenergic noncholinergic responses of opossum esophageal muscle. Am J Physiol. 1991;261:G401–6.
12. Murray JA, Ledlow A, Launspach J, Evans D, Loveday M, Conklin JL. The effects of recombinant human hemoglobin on esophageal motor functions in humans. Gastroenterology. 1995;109:1241–8.
13. Champion JK, Delise N, Hunt T. Myenteric plexus in spastic motility disorders. J Gastrointest Surg. 2001;5:514–6.
14. Kim HS, Park H, Lim JH, Choi SH, Park C, Lee SI, et al. Morphometric evaluation of oesophageal wall in patients with nutcracker oesophagus and ineffective oesophageal motility. Neurogastroenterol Motil. 2008;20:869–76.
15. Pehlivanov N, Liu J, Kassab GS, Beaumont C, Mittal RK. Relationship between esophageal muscle thickness and intraluminal pressure in patients with esophageal spasm. Am J Physiol Gastrointest Liver Physiol. 2002;282:G1016–23.
16. Katz PO, Dalton CB, Richter JE, Wu WC, Castell DO. Esophageal testing of patients with noncardiac chest pain or dysphagia. Results of three years’ experience with 1161 patients. Ann Intern Med. 1987;106:593–7.
17. Konturek T, Lembo A. Spasm, nutcracker, and IEM: real or manometry findings? J Clin Gastroenterol. 2008;42:647–51.
18. Pandolfino JE, Sifrim D. Evaluation of esophageal contractile propagation using esophageal pressure topography. Neurogastroenterol Motil. 2012;24 Suppl 1:20–6.
19. Roman S, Kahrilas PJ. Distal esophageal spasm. Dysphagia. 2012;27:115–23.
20. Ott DJ. Motility disorders of the esophagus. Radiol Clin N Am. 1994;32:1117–34.
21. Hewson EG, Ott DJ, Dalton CB, Chen YM, Wu WC, Richter JE. Manometry and radiology. Complementary studies in the assessment of esophageal motility disorders. Gastroenterology. 1990;98: 626–32.
22. Burmeister S. Review of current diagnosis and management of diffuse esophageal spasm, nutcracker esophagus/spastic nutcracker and hypertensive lower esophageal sphincter. Curr Opin Otolaryngol Head Neck Surg. 2013;21:543–7.
23. Brand DL, Martin D, Pope CE. II Esophageal manometrics in patients with angina-like chest pain. Am J Dig Dis. 1977;22:300–4.
24. Lufrano R, Heckman MG, Diehl N, Devault KR, Achem SR. Nutcracker esophagus: demographic, clinical features, and esophageal tests in 115 patients. Dis Esophagus. 2013. This a large case series of NE that describes the relevant clinical manifestations, comorbidities, and esophageal testing findings in patients with this motor disorder.
25. Mittal RK, Kassab G, Puckett JL, Liu J. Hypertrophy of the muscularis propria of the lower esophageal sphincter and the body of the esophagus in patients with primary motility disorders of the esophagus. Am J Gastroenterol. 2003;98:1705–12.
26. Jung HY, Puckett JL, Bhalla V, Rojas-Feria M, Bhargava V, Liu J, et al. Asynchrony between the circular and the longitudinal muscle contraction in patients with nutcracker esophagus. Gastroenterology. 2005;128:1179–86.
27. Korsapati H, Babaei A, Bhargava V, Mittal RK. Cholinergic stimulation induces asynchrony between the circular and longitudinal muscle contraction during esophageal peristalsis. Am J Physiol Gastrointest Liver Physiol. 2008;294:G694–8.
28. Korsapati H, Bhargava V, Mittal RK. Reversal of asynchrony between circular and longitudinal muscle contraction in nutcracker esophagus by atropine. Gastroenterology. 2008;135:796–802.
29. Agrawal A, Hila A, Tutuian R, Mainie I, Castell DO. Clinical relevance of the nutcracker esophagus: suggested revision of criteria for diagnosis. J Clin Gastroenterol. 2006;40:504–9.
30. Roman S, Kahrilas PJ. Challenges in the swallowing mechanism: nonobstructive dysphagia in the era of high-resolution manometry and impedance. Gastroenterol Clin North Am. 2011,40:823–835, ix-x.
31. Roman S, Pandolfino JE, Chen J, Boris L, Luger D, Kahrilas PJ. Phenotypes and clinical context of hypercontractility in highresolution esophageal pressure topography (EPT). Am J Gastroenterol. 2012;107:37–45. This paper shows the EPT plots findings in the extreme hypercontractile disorder called jackhammer esophagus. Different phenotypes based on single or multipeaked contractions and clinical manifestations are described.
32. Fontes LH, Herbella FA, Rodriguez TN, Trivino T, Farah JF. Progression of diffuse esophageal spasm to achalasia: incidence and predictive factors. Dis Esophagus. 2013;26:470–4.
33. Paterson WG, Beck IT, Da Costa LR. Transition from nutcracker esophagus to achalasia. A case report. J Clin Gastroenterol. 1991;13:554–8.
34. Anggiansah A, Bright NF, McCullagh M, Owen WJ. Transition from nutcracker esophagus to achalasia. Dig Dis Sci. 1990;35: 1162–6.
35. Achem SR, Kolts BE. Current medical therapy for esophageal motility disorders. Am J Med. 1992;92:98S–105.
36. Schmulson MJ, Valdovinos MA. Current and future treatment of chest pain of presumed esophageal origin. Gastroenterol Clin N Am. 2004;33:93–105.
37. Nguyen TM, Eslick GD. Systematic review: the treatment of noncardiac chest pain with antidepressants. Aliment Pharmacol Ther. 2012;35:493–500.
38. Clarke JO, Pandolfino JE. Esophageal motor disorders: how to bridge the gap between advanced diagnostic tools and paucity of therapeutic modalities? J Clin Gastroenterol. 2012;46:442–8.
39. Lacy BE, Weiser K. Esophageal motility disorders: medical therapy. J Clin Gastroenterol. 2008;42:652–8.
40. Lee H, Kim JH, Min BH, Lee JH, Son HJ, Kim JJ, et al. Efficacy of venlafaxine for symptomatic relief in young adult patients with functional chest pain: a randomized, double-blind, placebo-controlled, crossover trial. Am J Gastroenterol. 2010;105:1504–12.
41. Cannon RO, Quyyumi AA, Mincemoyer R, Stine AM, Gracely RH, Smith WB, et al. Imipramine in patients with chest pain despite normal coronary angiograms. N Engl J Med. 1994;330:1411–7.
42. Varia I, Logue E, O’Connor C, Newby K, Wagner HR, Davenport C, et al. Randomized trial of sertraline in patients with unexplained chest pain of noncardiac origin. Am Heart J. 2000;140:367–72.
43. Clouse RE, Lustman PJ, Eckert TC, Ferney DM, Griffith LS. Lowdose trazodone for symptomatic patients with esophageal contraction abnormalities. A double-blind, placebo-controlled trial. Gastroenterology. 1987;92:1027–36.
44. Spinhoven P, Van der Does AJ, Van Dijk E, Van Rood YR. Heartfocused anxiety as a mediating variable in the treatment of noncardiac chest pain by cognitive-behavioral therapy and paroxetine. J Psychosom Res. 2010;69:227–35.
45. Richter JE, Dalton CB, Buice RG, Castell DO. Nifedipine: a potent inhibitor of contractions in the body of the human esophagus. Studies in healthy volunteers and patients with the nutcracker esophagus. Gastroenterology. 1985;89:549–54.
46. Davies HA, Lewis MJ, Rhodes J, Henderson AH. Trial of nifedipine for prevention of oesophageal spasm. Digestion. 1987;36:81–3.
47. Richter JE, Spurling TJ, Cordova CM, Castell DO. Effects of oral calcium blocker, diltiazem, on esophageal contractions. Studies in volunteers and patients with nutcracker esophagus. Dig Dis Sci. 1984;29:649–56.
48. Drenth JP, Bos LP, Engels LG. Efficacy of diltiazem in the treatment of diffuse oesophageal spasm. Aliment Pharmacol Ther. 1990;4:411–6.
49. Eherer AJ, Schwetz I, Hammer HF, Petnehazy T, Scheidl SJ, Weber K, et al. Effect of sildenafil on oesophageal motor function in healthy subjects and patients with oesophageal motor disorders. Gut. 2002;50:758–64.
50. Lee JI, Park H, Kim JH, Lee SI, Conklin JL. The effect of sildenafil on oesophagealmotor function in healthy subjects and patients with nutcracker oesophagus. Neurogastroenterol Motil. 2003;15:617–23.
51. Fox M, Sweis R, Wong T, Anggiansah A. Sildenafil relieves symptoms and normalizes motility in patients with oesophageal spasm: a report of two cases. Neurogastroenterol Motil. 2007;19: 798–803.
52. Venes DJ. Imipramine in patients with chest pain despite normal coronary angiograms. N Engl J Med. 1994;331:882. author reply 882–883.
53. Maradey-Romero C, Fass R. New therapies for non-cardiac chest pain. Curr Gastroenterol Rep. 2014;16:390.
54. Achem SR, Kolts BE, MacMath T, Richter J, Mohr D, Burton L, et al. Effects of omeprazole versus placebo in treatment of noncardiac chest pain and gastroesophageal reflux. Dig Dis Sci. 1997;42: 2138–45.
55. Crozier RE, Glick ME, Gibb SP, Ellis FH Jr., Veerman JM. Acidprovoked esophageal spasm as a cause of noncardiac chest pain. Am J Gastroenterol. 1991;86:1576–80.
56. O’Neill OM, Johnston BT, Coleman HG. Achalasia: a review of clinical diagnosis, epidemiology, treatment and outcomes. World J Gastroenterol. 2013;19:5806–12.
57. Ramzan Z, Nassri AB. The role of botulinum toxin injection in the management of achalasia. Curr Opin Gastroenterol. 2013;29:468–73.
58. Storr M, Allescher HD, Rosch T, Born P, Weigert N, Classen M. Treatment of symptomatic diffuse esophageal spasm by endoscopic injection of botulinum toxin: a prospective study with long term follow-up. Gastrointest Endosc. 2001;54:18A.
59. Miller LS, Parkman HP, Schiano TD, Cassidy MJ, Ter RB, Dabezies MA, et al. Treatment of symptomatic nonachalasia esophageal motor disorders with botulinum toxin injection at the lower esophageal sphincter. Dig Dis Sci. 1996;41:2025–31.
60. Miller LS, Pullela SV, Parkman HP, Schiano TD, Cassidy MJ, Cohen S, et al. Treatment of chest pain in patients with noncardiac, nonreflux, nonachalasia spastic esophageal motor disorders using botulinum toxin injection into the gastroesophageal junction. Am J Gastroenterol. 2002;97:1640–6.
61. Vanuytsel T, Bisschops R, Farre R, Pauwels A, Holvoet L, Arts J, et al. Botulinum toxin reduces dysphagia in patients with nonachalasia primary esophageal motility disorders. Clin Gastroenterol Hepatol. 2013;11:1115–21. This is the first randomized controlled trial showing promising effects of Botox injection in the management esophageal symptoms in patients with DES and NE.
62. Irving JD, Owen WJ, Linsell J, McCullagh M, Keightley A, Anggiansah A. Management of diffuse esophageal spasm with balloon dilatation. Gastrointest Radiol. 1992;17:189–92.
63. Inoue H, Tianle KM, Ikeda H, Hosoya T, Onimaru M, Yoshida A, et al. Peroral endoscopic myotomy for esophageal achalasia: technique, indication, and outcomes. Thorac Surg Clin. 2011;21: 519–25.
64. Stavropoulos SN, Desilets DJ, Fuchs KH, Gostout CJ, Haber G, Inoue H, et al. Per-oral endoscopic myotomy white paper summary. Surg Endosc. 2014;28:2005–19.
65. Teitelbaum EN, Soper NJ, Santos BF, Arafat FO, Pandolfino JE, Kahrilas PJ, et al. Symptomatic and physiologic outcomes one year after peroral esophageal myotomy (POEM) for treatment of achalasia. Surg Endosc. 2014.
66. Shiwaku H, Inoue H, Beppu R, Nakashima R, Minami H, Shiroshita T, et al. Successful treatment of diffuse esophageal spasm by peroral endoscopic myotomy. Gastrointest Endosc. 2013;77:149–50.
67. Khashab MA, Saxena P, Kumbhari V, Nandwani M, Roland BC, Stein E, et al. Peroral endoscopic myotomy as a platform for the treatment of spastic esophageal disorders refractory to medical therapy (with video). Gastrointest Endosc. 2014;79:136–9.
68. Louis H, Covas A, Coppens E, Deviere J. Distal esophageal spasm treated by peroral endoscopic myotomy. Am J Gastroenterol. 2012;107:1926–7. This study reports POEM as a potential therapeutic technique for the treatment of DES.
69. Kandulski A, Fuchs KH, Weigt J, Malfertheiner P. Jackhammer esophagus: high-resolution manometry and therapeutic approach using peroral endoscopicmyotomy (POEM). Dis Esophagus. 2014.
70. Leconte M, Douard R, Gaudric M, Dumontier I, Chaussade S, Dousset B. Functional results after extended myotomy for diffuse oesophageal spasm. Br J Surg. 2007;94:1113–8.
71. Henderson RD, Ryder D, Marryatt G. Extended esophageal myotomy and short total fundoplication hernia repair in diffuse esophageal spasm: five-year review in 34 patients. Ann Thorac Surg. 1987;43:25–31.
72. Patti MG, Pellegrini CA, Arcerito M, Tong J, Mulvihill SJ, Way LW. Comparison of medical and minimally invasive surgical therapy for primary esophageal motility disorders. Arch Surg. 1995;130:609–15. discussion 615–606.
73. Lahcene M, Oumnia N, Matougui N, Boudjella M, Tebaibia A, Touchene B. Esophageal involvement in scleroderma: clinical, endoscopic, and manometric features. ISRN Rheumatol. 2011;2011:325826.
74. Gustafsson RJ, Littorin B, Berntorp K, Frid A, Thorsson O, Olsson R, et al. Esophageal dysmotility ismore common than gastroparesis in diabetes mellitus and is associated with retinopathy. Rev Diabet Stud. 2011;8:268–75.
75. Diener U, Patti MG, Molena D, Fisichella PM, Way LW. Esophageal dysmotility and gastroesophageal reflux disease. J Gastrointest Surg. 2001;5:260–5.
76. Ho SC, Chang CS, Wu CY, Chen GH. Ineffective esophageal motility is a primary motility disorder in gastroesophageal reflux disease. Dig Dis Sci. 2002;47:652–6.
77. Kahrilas PJ, Dodds WJ, Hogan WJ, Kern M, Arndorfer RC, Reece A. Esophageal peristaltic dysfunction in peptic esophagitis. Gastroenterology. 1986;91:897–904.
78. Timmer R, Breumelhof R, Nadorp JH, Smout AJ. Oesophageal motility and gastro-oesophageal reflux before and after healing of reflux oesophagitis. A study using 24 hour ambulatory pH and pressure monitoring. Gut. 1994;35:1519–22.
79. Cheng L, Cao W, Fiocchi C, Behar J, Biancani P, Harnett KM. Platelet-activating factor and prostaglandin E2 impair esophageal ACh release in experimental esophagitis. AmJ Physiol Gastrointest Liver Physiol. 2005;289:G418–28.
80. Rieder F, Cheng L, Harnett KM, Chak A, Cooper GS, Isenberg G, et al. Gastroesophageal reflux disease-associated esophagitis induces endogenous cytokine production leading to motor abnormalities. Gastroenterology. 2007;132:154–65.
81. Cao W, Cheng L, Behar J, Fiocchi C, Biancani P, Harnett KM. Proinflammatory cytokines alter/reduce esophageal circular muscle contraction in experimental cat esophagitis. Am J Physiol Gastrointest Liver Physiol. 2004;287:G1131–9.
82. Zhang X, Geboes K, Depoortere I, Tack J, Janssens J, Sifrim D. Effect of repeated cycles of acute esophagitis and healing on esophageal peristalsis, tone, and length. Am J Physiol Gastrointest Liver Physiol. 2005;288:G1339–46.
83. Richter JE, Blackwell JN, Wu WC, Johns DN, Cowan RJ, Castell DO. Relationship of radionuclide liquid bolus transport and esophageal manometry. J Lab Clin Med. 1987;109:217–24.
84. Blonski W, Vela M, Safder A, Hila A, Castell DO. Revised criterion for diagnosis of ineffective esophageal motility is associated with more frequent dysphagia and greater bolus transit abnormalities. Am J Gastroenterol. 2008;103:699–704.
85. Roman S, Lin Z, Kwiatek MA, Pandolfino JE, Kahrilas PJ. Weak peristalsis in esophageal pressure topography: classification and association with dysphagia. Am J Gastroenterol. 2011;106:349–56. This study proposes a new classification for weak peristalsis based on the presence of breaks in the proximal and distal esophageal body. This new classification correlates with dysphagia and abnormal esophageal bolus transit.
86. Xiao Y, Kahrilas PJ, Nicodeme F, Lin Z, Roman S, Pandolfino JE. Lack of correlation between HRM metrics and symptoms during the manometric protocol. Am J Gastroenterol. 2014;109:521–6.
87. Kumar N, Porter RF, Chanin JM, Gyawali CP. Analysis of intersegmental trough and proximal latency of smooth muscle contraction using high-resolution esophageal manometry. J Clin Gastroenterol. 2012;46:375–81. This paper demonstrated that extended proximal latency and transitional zone defects support the presence of esophageal hypomotility as a mechanism of esophageal symptoms.
88. Fibbe C, Layer P, Keller J, Strate U, Emmermann A, Zornig C. Esophageal motility in reflux disease before and after fundoplication: a prospective, randomized, clinical, and manometric study. Gastroenterology. 2001;121:5–14.
89. Novitsky YW, Wong J, Kercher KW, Litwin DE, Swanstrom LL, Heniford BT. Severely disordered esophageal peristalsis is not a contraindication to laparoscopic Nissen fundoplication. Surg Endosc. 2007;21:950–4.
90. Chrysos E, Tsiaoussis J, Zoras OJ, Athanasakis E, Mantides A, Katsamouris A, et al. Laparoscopic surgery for gastroesophageal reflux disease patients with impaired esophageal peristalsis: total or partial fundoplication? J Am Coll Surg. 2003;197:8–15.
91. Heading RC. Should abnormal oesophageal motility in gastrooesophageal reflux disease (GORD) influence decisions about fundoplication? Gut. 2002;50:592–3.
92. Cho YK, Choi MG, Park EY, Lim CH, Kim JS, Park JM, et al. Effect of mosapride combined with esomeprazole improves esophageal peristaltic function in patients with gastroesophageal reflux disease: a study using high resolution manometry. Dig Dis Sci. 2013;58:1035–41.
93. Chen CL, Yi CH, Liu TT, Orr WC. Effects of mosapride on secondary peristalsis in patients with ineffective esophageal motility. Scand J Gastroenterol. 2013;48:1363–70.
94. Agrawal A, Hila A, Tutuian R, Mainie I, Castell DO. Bethanechol improves smooth muscle function in patients with severe ineffective esophageal motility. J Clin Gastroenterol. 2007;41:366–70.
95. O’Rourke A, Weinberger P, Morrison M, Conklin J, Postma G. Topical bethanechol for the improvement of esophageal dysmotility: a pilot study. Ann Otol Rhinol Laryngol. 2013;122: 481–6.
96. Scarpellini E, Vos R, Blondeau K, Boecxstaens V, Farre R, Gasbarrini A, et al. The effects of itopride on oesophageal motility and lower oesophageal sphincter function in man. Aliment Pharmacol Ther. 2011;33:99–105.